

Please replace paragraph [0029] on page 13 with the following paragraph:

C<sub>1</sub> [0029] FIGURE 4. Sequence alignment of putative RNA helicases. Clustal W alignment of helicase domains of putative RNA helicases that share the RNA helicase motifs with *mda-5*. Conserved residues in DExH group RNA helicase defined in Jankowsky and Jankowsky, 2000, *Nucleic Acids Res* 28:333-334, are aligned with consensus sequence (uppercase Roman numeric). Those underlined and marked with lowercase Roman numeric are for conserved motifs in this subgroup. Asterisks (\*) = identical residues; colons (:) = conserved substitutions; dots (.) = semiconserved substitutions. MDA-5 (SEQ ID NO.:2); Q9HAM6 (SEQ ID NO.:12); RHIV-1 (SEQ ID NO.:13); RIG-1 (SEQ ID NO.:14); P34529 (SEQ ID NO.:15); Q9SP32 (SEQ ID NO.:16); Q09884 (SEQ ID NO.: 17).

Please replace paragraph [0075] on pages 31 and 32 with the following paragraph:

C<sub>2</sub> [0075] *mda-5* Expression Vectors. A hemagglutinin (HA)-tagged *mda-5* fragment was obtained by reverse transcription-PCR, using primers 5'-GCCACCATGTACCCATACGACGTCCCAGACTACGCTATGTCGAATGGGTATTCCACAGACG-3' (SEQ ID NO:5) and 5'-TCACTAATCCTCATCACTAAATAAACAGC-3' (SEQ ID NO.:10), and was cloned into the EcoRV site of pcDEF3 with expression regulated by the EF-1 $\alpha$  promoter. An antisense *mda-5* expression vector was constructed by cloning the EagI/SpeI *mda-5* genomic DNA (3.8-kbp) fragment from a bacterial artificial chromosome clone into the SpeI/NotI site of pcDEF3. The genomic DNA fragment consists of the first exon and part of the first intron. A green fluorescent protein (GFP)-*mda-5* fusion expression vector was constructed by ligation of an *mda-5* cDNA product, derived by reverse transcription-PCR using the primers

5'-ATGTCGAATGGGTATTCCACAGACG-3' (SEQ ID NO:6) and 5'-  
TTTTTTTTTTTCAGAGTAAAACAATC-3' (SEQ ID NO.:11), into the SmaI site of pEGFP-  
C2 (CLONTECH).

---

IN THE DRAWINGS:

Please amend Figure 3 as indicated on the enclosed corrected version of the figure, wherein the desired corrections are marked in red.

REMARKS

Applicants respectfully submit herewith a Sequence Listing in paper and computer-readable form. Please enter this Sequence Listing into the specification of the above-captioned application.

I hereby state that the content of the paper and computer readable copies of the revised Sequence Listing submitted in accordance with 37 C.F.R. §§ 1.821(c) and (e), respectively, are the same.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted herewith in accordance with 37 C.F.R. § 1.82(f), does not include new matter.

It is noted that the Sequence Listing provided herewith contains the correct sequence as illustrated in Figure 3, amended herein, consistent with the identification of the sequence in the specifications, Sequence Listings, and drawings of parent applications PCT/US01/06960 and U.S. Ser. No. 09/515,363.

Applicants also respectfully request the amendment of Figure 3 of the above-identified application to correct typographical errors present in the figure. Due to technical errors, two